Entities / Company
Hutchison MediPharma Limited.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 14
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
AstraZeneca paid a milestone payment to Hutchison MediPharma Limited on August 7, 2025.Some support1 report
-
Hutchison MediPharma Limited's growth forecast was compared to the UK Pharma industry in August 2025.Some support1 report
-
Johnny Cheng was appointed Acting CEO of Hutchison MediPharma Limited on August 25, 2025.Some support1 report
-
Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Hutchison MediPharma Limited this week
News at the entities that move Hutchison MediPharma Limited most-
AstraZeneca StructuralAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Hutchison MediPharma Limited
Connections
The 1 strongest of 14, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AstraZeneca Structural
AstraZeneca and Hutchison MediPharma are engaged in a formal joint development and commercialization partnership for the drug savolitinib.
History
Events by the month they beganJune 2026
4 events- AstraZeneca paid a milestone payment to Hutchison MediPharma Limited on August 7, 2025.
- Hutchison MediPharma Limited's growth forecast was compared to the UK Pharma industry in August 2025.
- Johnny Cheng was appointed Acting CEO of Hutchison MediPharma Limited on August 25, 2025.
- Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.